Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
Treatment for Alcoholism and Post-Traumatic Stress Disorder (naltrexone) Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on Treatment for Alcoholism and Post-Traumatic Stress Disorder (naltrexone) conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Treatment for Alcoholism and Post-Traumatic Stress Disorder (naltrexone) Clinical research trials and Treatment for Alcoholism and Post-Traumatic Stress Disorder (naltrexone) healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including Treatment for Alcoholism and Post-Traumatic Stress Disorder (naltrexone). Treatment for Alcoholism and Post-Traumatic Stress Disorder (naltrexone) Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Treatment for Alcoholism and Post-Traumatic Stress Disorder (naltrexone) clinical trial. Test subjects typically receive the most effective healthcare possible for their Treatment for Alcoholism and Post-Traumatic Stress Disorder (naltrexone) condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.

Home > "T" Clinical Trials Conditions > Treatment for Alcoholism and Post-Traumatic Stress Disorder (naltrexone)

Treatment for Alcoholism and Post-Traumatic Stress Disorder (naltrexone)



Treatment for Alcoholism and Post-Traumatic Stress Disorder (naltrexone)

For Condition: Post-Traumatic Stress Disorder,Alcoholism
Status: Recruiting
Sponsor(s): National Institute on Alcohol Abuse and Alcoholism (NIAAA) ,
Synopsis: This study will evaluate naltrexone and cognitive-behavioral therapy treatments for alcohol dependence and post-traumatic stress disorder (PTSD). Subjects will be randomly assigned a 6-month treatment of either: 1) naltrexone alone, 2) naltrexone with PTSD psychosocial therapy, 3) a placebo with PTSD psychosocial therapy, or 4) placebo alone. An enhanced medication management intervention will accompany all treatment conditions. Followup assessments will be completed at 9 and 12 months after treatment.
Details:
Eligibility:
Study Type:
  Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Efficacy Study
Minimum Age/Maximum Age: 18 Years/65 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Meets criteria for alcohol dependence and post-traumatic stress disorder. - Heavy drinking in the past 30 days (an average of more than 12 alcohol drinks per week with at least 1 day of 4 or more drinks). - Successfully complete medical detoxification. - Exhibit clinically significant trauma-related symptoms. - Live in a commutable distance to the University of Pennsylvania and agree to followup visits. - Able to provide an informed consent. - Speak and read English. Exclusion Criteria: - Current diagnosis of any substance dependence other than alcohol, nicotine, or cannabis. - Evidence of opiate use in the past 30 days. - Significant risk of violence or history of serious violent behavior during the past year. - Receiving current treatment with any psychotropic medication (excluding short-term use of benzodiazepines for detoxification), including disulfiram. - Unstable or serious medical illness. - Current severe psychiatric symptoms. - Mental retardation or another pervasive developmental disorder. - Use of an investigational medication in the past 30 days. - Pregnant, nursing or not using reliable contraception.
Total Enrollment: 200

Location and Contact Information:

Center for Anxiety, University of Pennsylvania *Recruiting*
Philadelphia,  Pennsylvania,  19104
United States
Recruiting Dr.  Foa 215-746-3327


Additional Information:
Study ID Numbers:
  NIAAAFOA12428; 
Study Start Date: 
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006489

Other Post-Traumatic Stress Disorder Studies:
1. Trazodone for Sleep Disturbance in Early Alcohol Recovery

2. Treatment for Alcoholism and Post-Traumatic Stress Disorder (naltrexone)

3. Genetic Factors and Interrelationships for Cancer Risk-Related Behaviors and Complex Traits

4. Smoking Cessation in Alcoholism Treatment

5. Timing of Smoking Intervention in Alcohol Treatment (nicotine patch)

Related Studies:

Other Post-Traumatic Stress Disorder Clinical Trials
Other Pennsylvania Clinical Trials
Other Philadelphia Clinical Trials

Treatment for Alcoholism and Post-Traumatic Stress Disorder (naltrexone)

Modify your Search

  Other Post-Traumatic Stress Disorder Clinical Trials
  Other Pennsylvania Clinical Trials
  Other Philadelphia Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103